{
    "nctId": "NCT06081959",
    "briefTitle": "Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer",
    "officialTitle": "A Randomized, Open-label, Multicenter Phase 3 Study of SKB264 Versus Treatment of Physician's Choice (TPC) in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 376,
    "primaryOutcomeMeasure": "Progression-free survival (PFS) assessed by BIRC per RECIST 1.1.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Males or females aged \u2265 18 to \u2264 75 years at the time of signing the ICF;\n* Histologically and/or cytologically confirmed HR+/HER2- breast cancer based on pathology reports on recent biopsy specimens or other pathological samples;\n* Patients who had failed at least one line of systemic chemotherapy in unresectable locally advanced, recurrent, or metastatic stage;\n* Patients with at least one measurable lesion per RECIST 1.1 criteria; those with only skin or bone lesions cannot be included;\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1;\n* Expected survival \u2265 12 weeks;\n* Adequate organ and bone marrow function;\n* Patients who are eligible for a chemotherapy regimen in the control group;\n* Female patients of childbearing potential and male patients with partners of childbearing potential who use effective medical contraception from the time of signing the informed consent form until 6 months after the last dose;\n* Patients who voluntarily participate in the study and sign the ICF, and able to comply with the visit and related procedures stipulated in the plan.\n\nExclusion Criteria:\n\n* Patients with a history of central nervous system (CNS) metastases or current CNS metastases\uff1b\n* Patients with other malignancies (except cured basal or squamous cell skin cancer or carcinoma in situ of the cervix) within 3 years prior to the first dose;\n* Patients with any cardio cerebral Vascular disease or cardio cerebral vascular risk factors may affect investigational treatment;\n* Uncontrollable systemic diseases assessed by the investigator;\n* History of (noninfectious) interstitial lung disease (ILD)/noninfectious neumonitis requiring steroid therapy and current ILD/noninfectious pneumonitis, or ILD/noninfectious pneumonitis at screening that cannot be excluded by imaging;\n* Clinically serious lung injuries caused by lung diseases;\n* Patients with active chronic Inflammatory bowel disease, gastrointestinal obstruction, severe ulcer, gastrointestinal perforation, abdominal abscess or acute gastrointestinal bleeding;\n* Toxicities from prior anti-tumor therapy not recovering to \u2264 Grade 1;\n* Active hepatitis B or hepatitis C;\n* Human immunodeficiency virus (HIV) antibody test positive or a history of acquired immunodeficiency syndrome (AIDS), known active syphilis infection;\n* Known allergy or hypersensitivity to SKB264, or the excipients of SKB264;\n* Prior TROP2 targeted therapy, prior topoisomerase I inhibitor therapy, including antibody-drugconjugate(ADC) therapy;\n* Patients who received major surgeries 4 weeks prior to the first dose of study treatment or planned to receive major surgeries during the study ;\n* Patients with concomitant infections requiring systemic antibiotic therapy within 2 week prior to the first dose of study treatment;\n* Patients who have received live vaccines within 30 days prior to the first dose, or are scheduled to receive live vaccines during the study;\n* Pregnant or lactating women.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}